Voyager Therapeutics
VYGR
116 hedge funds and large institutions have $262M invested in Voyager Therapeutics in 2018 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 37 reducing their positions, and 22 closing their positions.
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
3% less funds holding
Funds holding: 119 → 116 (-3)
3.57% less ownership
Funds ownership: 89.13% → 85.56% (-3.6%)
14% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 37
52% less capital invested
Capital invested by funds: $547M → $262M (-$285M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$14.3M |
| 2 |
Renaissance Technologies
New York
|
+$4.58M |
| 3 |
HCM
Highline Capital Management
New York
|
+$3.63M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.4M |
| 5 |
SIM
Spark Investment Management
New York
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$13.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$12M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.01M |
| 4 |
TOPU
Trustees of Princeton University
Princeton,
New Jersey
|
-$3.85M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.43M |
VYGR Hedge Fund Activity: Q4 2018 in Review
116 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q4 2018, worth a combined $262M — down 52% from $547M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of VYGR and 20 opened new positions — a net loss of 2 holders — while 37 trimmed existing stakes and 32 added.
The largest buyer was Armistice Capital, adding an estimated $14.3M. The largest seller was Great Point Partners, cutting an estimated $13.3M.
- 116 institutional investors held Voyager Therapeutics (VYGR) as of Q4 2018, down from 119 in Q3 2018.
- Funds reported $262M of Voyager Therapeutics stock for Q4 2018, down 52% quarter-over-quarter.
- 20 funds opened new Voyager Therapeutics positions in Q4 2018 and 22 closed out, a net change of -2 holders.
- The largest Voyager Therapeutics buyer in Q4 2018 was Armistice Capital, an estimated $14.3M added.
- The largest Voyager Therapeutics seller in Q4 2018 was Great Point Partners, an estimated $13.3M sold.
Based on aggregated 13F filings for Q4 2018.